S&P 500 — US Large Cap Index
FTSE 100 — UK Blue Chips
Euro Stoxx 50 — Eurozone Leaders
DAX 40 — German Equities
CAC 40 — French Market Index
Nikkei 225 — Japan Benchmark
Hang Seng — Hong Kong Index
Shanghai Composite — China Mainland
ASX 200 — Australian Market
TSX Composite — Canada Index
Nifty 50 — India Large Cap
STI Index — Singapore Market
KOSPI — South Korea Index
Bovespa — Brazil Equities
JSE Top 40 — South Africa Index
IPC Index — Mexico Market
Shares of Hims & Hers Health (HIMS.US) shares exploded in pre-market trading today, rising by approximately 45-50 percent, following reports by Bloomberg that the company is resuming its partnership with Novo Nordisk (NOVOB.DK) and will sell branded weight loss drugs, including Wegovy, on its platform. NOVOB shares are up more than 1.5% today following the news. This is a radical turnaround just one month after Novo filed a patent lawsuit against Hims for copying semaglutide and after the earlier termination of the agreement in 2025, when the telemedicine company refused to give up selling cheaper, complex versions of GLP-1. The market interprets the new agreement as confirmation that Hims is gaining direct access to FDA-approved obesity drugs, which significantly reduces key regulatory and legal risks associated with its GLP-1 business, especially after the recent wave of FDA warning letters to telemedicine companies selling complex preparations. This update reduces the specter of protracted litigation and potential sanctions, while reclaiming the rapidly growing weight loss therapy market for Hims.
At the same time, it is worth remembering that the euphoria surrounding the stock market listing does not remove all the question marks surrounding Hims’ business model. The company still derives most of its revenue from other categories (hair, sexual health, mental health), and the weight loss segment, although it has enormous potential, is still in its infancy and remains subject to regulatory decisions and the terms of cooperation with large pharmaceutical companies.
Source: xStation
The material on this page does not constitute financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other specific needs. All information provided, including opinions, market research, mathematical results and technical analyzes published on the Website or transmitted To you by other means, it is provided for information purposes only and should in no way be construed as an offer or solicitation for a transaction in any financial instrument, nor should the information provided be construed as advice of a legal or financial nature on which any investment decisions you make should be based exclusively To your level of understanding, investment objectives, financial situation, or other specific needs, any decision to act on the information published on the Website or sent to you by other means is entirely at your own risk if you In doubt or unsure about your understanding of a particular product, instrument, service or transaction, you should seek professional or legal advice before trading. Investing in CFDs carries a high level of risk, as they are leveraged products and have small movements Often the market can result in much larger movements in the value of your investment, and this can work against you or in your favor. Please ensure you fully understand the risks involved, taking into account investments objectives and level of experience, before trading and, if necessary, seek independent advice.
